Teva Strikes $24M Deal To Exit Nexium Pay-For-Delay Suit
Class action plaintiffs in a pay-for-delay case over generic versions of AstraZeneca PLC's heartburn drug Nexium disclosed on Thursday a $24 million settlement freeing Teva Pharmaceutical Industries Ltd. from the case,...To view the full article, register now.
Already a subscriber? Click here to view full article